Special Issue

Emerging Therapeutic Candidates for Stroke Treatment

Message from the Guest Editors

Stroke continues to be a leading cause of death and long-term disability worldwide. There are two main types of stroke: ischemic and hemorrhagic stroke. Mechanical/pharmacologic reperfusion therapy is currently the most effective treatment for ischemic stroke, while the medical intervention for hemorrhagic stroke aims to remove the hematoma and stop bleeding, usually through a surgical procedure. Obviously, current therapeutic options for stroke patients, especially pharmacologic interventions, are very limited. In this regard, at least two categories of potential stroke therapeutics are urgently needed. The first category is cerebroprotective adjuvant agents that can decelerate the progression of stroke-induced brain injury and thus extend the therapeutic window. The second could be administered to augment the beneficial effects of acute treatment and/or promote brain recovery during the chronic stroke phase. We hope that this collection will serve as a valuable resource in the search for novel stroke treatments that will ultimately improve the quality of life of patients suffering from stroke.

Guest Editors

Dr. Wei Yang

Multidisciplinary Brain Protection Program (MBPP), Department of Anesthesiology, Duke University Medical Center, P.O. Box 3094, Durham, NC 27710, USA

Dr. Huaxin Sheng

Multidisciplinary Brain Protection Program (MBPP), Duke University Medical Center, P.O. Box 3094, Durham, NC 27710, USA

Deadline for manuscript submissions

closed (10 November 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/138835

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

